Multiple myeloma (MM) is a malignant B-cell disorder characterized by the accumulation of neoplastic plasma cells in the bone marrow (BM). One of the major characteristics of MM is the occurrence of bone lesions, caused by an imbalance between osteoblastic and osteoclastic function. Mesenchymal stem cells (MSCs) are a population of multipotent stem cells, which have the potential to differentiate into different mesenchymal tissues. Several previous studies indicated that BM-derived MSCs from MM patients showed an enhanced production of cytokines and a distinctive gene expression profile, as compared with their normal counterparts. [1] [2] [3] [4] Although osteoblastic function is decreased in advanced MM, regarding whether and at which level the differentiation of MSCs towards osteoblasts is impaired in this disease, the reports are not unanimous. [1] [2] [3] In the present study, MSCs from both normal subjects (healthy human donors or naive mice) and MM subjects (MM patients or 5T33MM mice) were used. The 5T33MM mice originate from elderly C57Bl/KaLwRij mice that spontaneously developed MM, and the MM model is propagated by intraveneous transfer of diseased BM cells into young syngeneic mice. 5 First, fresh BM was isolated from naive and 5T33MM mice, and the primary nucleated cell was analyzed by the CFU-F assay. In this in vitro assay, each CFU-F is derived from a single MSC. 6 To explore the osteogenic differentiation ability, preformed colonies were cultured in osteogenic medium (OM), and were then stained for alkaline phosphatase (ALP) as a marker for osteogenic commitment (CFU-Alp). The percentage of CFU-Alp per total CFU-F was significantly lower in diseased 5T33MM mice compared with the percentage observed in naive mice (Figure 1a) , suggesting primary MM mice-derived murine MSCs exhibit weaker osteogenic differentiation potential. To confirm this observation with human MSCs (hMSCs), we cultured and expanded in vitro BM-derived MSCs from normal donors (ND-hMSCs), from monoclonal gammopathy of undetermined significance (MGUS) patients (MGUShMSCs) and from MM patients with or without bone lesions (MMhMSCs) (primary culture of hMSCs and osteogenic induction is shown in Supplementary Information about Materials and Methods). For each group, the ALP activity of cultured cells (passage 2) was assessed after 72 h culture in OM. We observed that ALP activity in MGUS-hMSCs was slightly decreased as compared with ND-hMSCs. However, the ALP activity of MMhMSCs was always significantly lower. Interestingly, for MM patients with bone lesions, the ALP activity of MSCs is even significantly lower (Po0.001) as compared with MM patients without bone lesions (Po0.05). This suggests a defect in the osteogenic differentiation potential of MSCs in MM patients, especially in those with bone disease (Figure 1b) . Corre et al. 2 reported a striking reduction of mineralization for MM-hMSCs compared with ND-hMSCs but did not observe a decrease of ALP activity for MM-hMSCs. The discrepant results might result from the sample number and selection, and the difference in timing of ALP analysis between the studies. Next, we selected three ND-hMSCs samples and three MM-hMSCs samples (as circled in Figure 1b) , and confirmed that these MM-hMSCs had a remarkably lower ALP activity, matrix mineralization and increasing level of osteogenic markers (Figures 1c, d and e). These measurements confirmed that the ability of MSCs from MM patients with bone lesions to undergo osteogenic differentiation was significantly impaired. However, ND-hMSCs and MMhMSCs expressed the same phenotype Figure 1) . In addition, it is well known that Runx2 is an important transcription factor involved in the osteogenic differentiation of MSC. We found that the baseline expression of Runx2 in both hMSCs is comparable. However, after culturing in OM for 24 h, the increase of Runx2 in ND-hMSCs was higher compared with MM-hMSCs (Supplementary Figure 2) .
Previous reports indicated that MM cells could suppress MSCs osteogenesis by several molecules.
7-10 As we have cultured and expanded MM-hMSCs in vitro in the absence of MM cells, the impaired osteogenic differentiation of MM-hMSCs seems not to result from the factors produced by MM cells directly, but might be due to intrinsic abnormalities in cellular signaling pathways or gene expression. Notch signaling has a key role in the development and differentiation during embryogenesis and in postnatal life. Several groups reported that Notch signaling could maintain BM mesenchymal progenitors in a more undifferentiated state by suppressing osteoblast differentiation.
11-14 Therefore, we aim to investigate how Notch signaling relates to the osteogenic differentiation of MM-hMSCs with reduced osteogenic capacity. We first evaluated the expression of several Notch signaling elements (including Notch receptors Notch1 and Notch2, and Notch signaling downstream genes hes1, hes5, hey1, hey2 and heyL) in ND-hMSCs by quantitative PCR (qPCR) (Primer sequences are listed in Supplementary Table) . After culturing in OM for 7 days, Notch signaling activity of ND-hMSCs was found to be widely suppressed, which was in accordance with the negative effect of Notch signaling in MSC osteogenesis reported. However, we observed that Notch signaling activity of MM-hMSCs was not decreased to the level found in ND-hMSCs. Among all tested genes, the expression of Notch1, hes1 and hes5 was significantly different (Figure 2a) . To demonstrate that Notch signaling was directly related to suppression of MM-hMSCs differentiation to osteoblasts, we treated MM-hMSCs with DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a g-secretase inhibitor of Notch signaling. Addition of DAPT enhanced in MM-hMSCs the expression of Runx2 and reduced levels of hes1, suggesting that these effects were mediated via Notch signaling (Figure 2b) . qRT-PCR analysis showed that inhibition of Notch signaling enhanced the expression of osteogenic markers (Figure 2c ). The DAPT-treated MM-hMSCs also showed remarkably increased ALP activity and mineralization deposition compared with vehicle cultures (Figures 2d and e) . Moreover, Notch1 knockdown by RNA interference confirmed that the inhibition of Notch signaling could restore the osteogenic differentiation in MM-hMSCs (Supplementary Figure 4) . A similar, but less pronounced increase of osteogenic differentiation was observed after DAPT treatment or Notch1 knockdown in ND-hMSCs (Supplementary Figures 3 and 5) .
Nowadays, it is widely accepted that MM evolves in all patients from a pre-existing MGUS stage, although in many MM patients this premalignant stage might be unrecognized clinically owing to its asymptomatic nature. We found that MGUS-hMSCs did not show significantly decreased osteoblastogenic differentiation, which suggested that the abnormality of MM-hMSCs is mostly 'acquired' during or after the transition from MGUS to MM. Our data do not allow to conclude whether the impaired osteogenic differentiation of MM-hMSCs is due to an inherent difference, although the genomic profile in ND-hMSCs and MMhMSCs was reported to be much different. 4 We assume that with the persistent stimulation of MM cells in vivo, hMSCs gradually gain abnormalities in gene expression and/or certain signaling pathways of osteoblast differentiation, such as Notch signaling. These abnormalities of MM-hMSCs might still exist in vitro even though MM cells are removed.
In addition, we investigated whether Notch pathway inhibition could increase bone formation in vivo. Compared with naive mice, osteoblasts were almost totally suppressed in the 5T33MM mice due to the strong inhibition by MM cells (Figure 2f ). Naive or 5T33MM mice were injected with DAPT or vehicle daily for 20 dosages. For naive mice, the primary colony number in CFU-F assay decreased significantly after DAPT treatment, indicating a loss of primary MSC pool. Meanwhile, treatment with DAPT induced a one third-fold increase in osteoblast cell number in naive mice (Figure 2g) . However, for MM mice, Notch inhibitor treatment had no remarkable effect either on tumor burden in the bone, or on osteoblast cells number and bone formation (Figure 2h ). Why discrepant results came out between noncancerous and MM mice? Obviously, the 'powerful' inhibition from MM cells could not be ignored. As mentioned earlier, MM cells have been reported to inhibit osteoblastogenesis by multiple molecules. [7] [8] [9] [10] Single use of NOTCH inhibitor could not decrease MM tumor burden in the BM (Figure 2h) , so these MM cell-derived molecules continuously exert inhibitory effects on MSC osteogenic differentiation. In addition, in a preclinical study by He et al., 15 it was found that a high level of tumor-derived interleukin 6 (IL6) and IL8 in solid tumors could significantly abrogate the efficacy of the g-secretase inhibitor. It is known that IL6 is an important MM cell growth factor and our group recently confirmed that 5T33MM mice showed a higher IL6 expression in the BM microenvironment as well as an increased IL6 level in the plasma as compared with naive mice (unpublished data). Therefore, a more efficient effect on bone formation might be achieved by combining the Notch inhibitor with other anti-MM drugs or an IL6 antagonist.
In summary, we demonstrated for the first time, that BM derived MSCs from MM patients, but not from MGUS patients, have an impaired osteogenic differentiation potential. In normal hMSCs, downregulation of Notch signaling occurs during the process of osteogenesis. However, Notch signaling of MM-hMSCs fails to reach the low expression level observed in ND-hMSCs. It seems that maintenance of Notch signaling activity in MM-hMSCs relates to a suppression of the osteogenic differentiation in these stem cells. Combining anti-MM drugs or an IL6 antagonist with a Notch Figure 1 . MM BM-derived MSCs showed impaired osteogenic differentiation potential. (a) Primary BM cells from naive and 5T33MM mice were cultured for colony formation: CFU-F in basic growth medium, CFU-Alp in OM performed with ALP staining by BCIP/NBT solution (SigmaAldrich). n ¼ 6/group. A representative CFU-Alp is shown. Original magnification, Â 40. Scale bar, 100 mm. (b) hMSCs in passage 2 from normal donors, MGUS patients and MM patients were cultured in OM for 72 h and their ALP activities were measured using ALP yellow liquid substrate system for ELISA (Sigma-Aldrich) at 415 nm. To exclude that observed differences were due to differential cell proliferation, ALP activity was normalized to total protein determined with a Pierce BCA Protein Assay (Thermo Fisher Scientific, Epsom, UK) to determine ALP index (ALP index ¼ ALP spectrophotometer reading/protein Â 1000). Three ND-hMSC samples and three MM-hMSC samples (as circled) were selected for the following experiment. (c) Selected ND-hMSCs and MM-hMSCs were assessed for their osteoblastic differentiation potential by ALP staining. ALP staining for hMSCs was performed by BCIP/NBT solution (Sigma-Aldrich) after 7 days cultured in OM. (d) Selected ND-hMSCs and MM-hMSCs were assessed for their mineralization deposition by alizarin red S staining. Alizarin red S staining was performed after 14 days culturing in OM. Original magnification, Â 100. Scale bar, 100 mm. (e) Selected ND-hMSCs showed a higher upregulation of osteogenesisrelated markers by qPCR after culturing in OM for 7 days compared with selected MM-hMSCs. All values are expressed as mean±SD. *Po0.05; **Po0.01; ***Po0.001; NS, not significant.
inhibitor might be an effective approach to promote osteoblastogenesis and control bone disease in MM patients. 
